volcano plot analysis highlighted galectin 7 (Galectin Therapeutics)
86
Structured Review
Galectin Therapeutics
volcano plot analysis highlighted galectin 7
Volcano Plot Analysis Highlighted Galectin 7, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plot+analysis/pmc12704086-165-0-4
Average 86 stars, based on 1 article reviews
Volcano Plot Analysis Highlighted Galectin 7, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plot+analysis/pmc12704086-165-0-4
Average 86 stars, based on 1 article reviews
volcano plot analysis highlighted galectin 7 - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Expressing:Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment Article Snippet: To validate the spatial transcriptomic findings at the protein level, immunohistochemistry for p63 and Galectin-7 was performed on the same cystectomy specimen used for Visium HD analysis. .. Consistent with the transcriptomic data, p63 was broadly expressed in both UC and Ba/Sq-differentiated tumor components, whereas Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment Article Snippet: A Immunohistochemistry (IHC) for p63 and Galectin-7 in UC with Ba/Sq features ( n = 28) and UC without Ba/Sq ( n = 64). .. B Immunohistochemistry (IHC) of three representative UC with Ba/Sq differentiation cases showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment Article Snippet: Galectin-7 (encoded by LGALS7 ) is a β-galactoside-binding lectin family involved in apoptosis, cell adhesion, and inflammatory signaling [ ]. .. It is highly expressed in normal stratified epithelia, and Article Title: Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer. Article Snippet: Galectins (GALs) act as glyco-immune checkpoints that modulate tumor immunity, but their overlapping expression complicates functional dissection and targeted inhibition.. Here, we explore the distinct molecular and immunological roles of GAL-1 and GAL-7, two GAL sover expressed in triple-negative breast cancer (TNBC), and describe the development of highly selective nanobody-derived minibodies (G1M1 and G7M8) that specifically target each protein.. In TNBC cells, GAL-1 and GAL-7 induced different cytokine profiles: GAL-1 increased pro-tumor mediators such as G-CSF and VEGF-A, while GAL-7 promoted immunomodulatory cytokines, highlighting their nonredundant functions. Immunohistochemistry:Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment Article Snippet: A Immunohistochemistry (IHC) for p63 and Galectin-7 in UC with Ba/Sq features ( n = 28) and UC without Ba/Sq ( n = 64). .. B Immunohistochemistry (IHC) of three representative UC with Ba/Sq differentiation cases showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and Activity Assay:Article Title: Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer. Article Snippet: Galectins (GALs) act as glyco-immune checkpoints that modulate tumor immunity, but their overlapping expression complicates functional dissection and targeted inhibition.. Here, we explore the distinct molecular and immunological roles of GAL-1 and GAL-7, two GAL sover expressed in triple-negative breast cancer (TNBC), and describe the development of highly selective nanobody-derived minibodies (G1M1 and G7M8) that specifically target each protein.. In TNBC cells, GAL-1 and GAL-7 induced different cytokine profiles: GAL-1 increased pro-tumor mediators such as G-CSF and VEGF-A, while GAL-7 promoted immunomodulatory cytokines, highlighting their nonredundant functions. |